← SynDRA
ENCORAFENIB
SynDRA canonical compound SYN0038042 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | BRAF | CCND1 |
|---|
| Mechanism of action | RAF inhibitor | serine/threonine kinase inhibitor |
|---|
| Indication | melanoma |
|---|
| Disease area | oncology |
|---|
All known targets
- BRAF
- MAPK14
- RIPK3
- RIPK2
- RAF1
- PGRMC1
- PCYT1A
- NLK
- MAPKAPK2
- MAPK9
- MAPK8
- MAP3K4
Mechanisms of action (all sources)
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
- RAF inhibitor
- serine/threonine kinase inhibitor
- BRAF MODULATOR
- RAF1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE4D
- CHRM3
- AAK1
- NTRK1
- PAICS
- OPRM1
- OPRK1
- OPRD1
- OPA1
- OLA1
- NUAK2
- NR3C1
- PAK4
- NR1I2
- NQO2
- NPY1R
- NEK9
- NEK3
- NEK2
- NEK1
- NDUFA13
- PAK2
- PASK
- PRKACG
- PIP4K2C
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2A
- PDE3A
- PIM1
- PHKG2
- PGR
- PFKP
- PEBP1
- PDXK
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- BRAFTOVI
- Braftovi
- braftovi
- NVP-LGX818-NXA
- Lgx-818
- Lgx818
- NVP-LGX-818-NXA
- NVP-LGX818
- LGX818
- LGX 818
- Encorafenib (LGX818)
- UNII-8L7891MRB6
- 8L7891MRB6
- Encorafenib [USAN:INN]
- LGX-818(Encorafenib)
- Braftovi (TN)
- ENCORAFENIB [MI]
- Encorafenib(LGX-818)
- ENCORAFENIB [INN]
- ENCORAFENIB [JAN]
- ENCORAFENIB [USAN]
- ENCORAFENIB [WHO-DD]
- Encorafenib (JAN/USAN/INN)
- GTPL7908
- SCHEMBL8228295
- CHEMBL3301612
- DTXSID00155347
- ENCORAFENIB [ORANGE BOOK]
- BDBM221688
- BCP08458
- EX-A1587
- MFCD25976758
- NSC778304
- NSC800093
- s7108
- ZINC68249103
- CCG-269960
- DB11718
Reported adverse events
- Abdominal pain
- Alopecia
- Arthralgia
- Constipation
- Dermatitis
- Dermatitis acneiform
- Dizziness
- Dry skin
- Dysgeusia
- Erythema
- Fatigue
- Headache
Look up ENCORAFENIB in the interactive SynDRA portal →